The Safety of Ovarian Preservation in Stage IA Endometrial Carcinoma

NCT01820884 · tracked via the Priya Life Science China tracker

Sponsor

Ding Ma

Phase

Not applicable

Started

2012-11

Last updated

2024-04-02

Condition(s) studied

Endometrial Neoplasms

Investigational drug(s) / intervention(s)

THTH/BSOBPLND

TH: Total hysterectomy

TH/BSO: Total hysterectomy and bilateral salpingo-oophorectomy

BPLND: bilateral pelvic and para-aortic lymph node dissection

Study summary

This randomized trial is studying the efficacy and safety of the hysterectomy alone compared with hysterectomy and bilateral salpingo-oophorectomy (BSO) for patients with Stage IA endometrial carcinoma.

Eligibility

Sex

FEMALE

Min age

18 Years

Max age

50 Years

Healthy volunteers

Inclusion Criteria: * FIGO stage: ⅠA, endometrial carcinoma; * Female, Chinese women; * premenopausal women； * ≤ 50 years old; * Pathological diagnosis by curettage/hysteroscopy : G1 * No prior treatment; * Provide written informed consent. Exclusion Criteria: * The suspicious metastasis of ovarian; * Family history of ovarian cancer; * Suffering from other malignancies; * Concurrently participating in other clinical trials; * Unable or unwilling to sign informed consents; * Unable or unwilling to abide by protocol.

Primary outcome measure(s)

Disease-free survival (DFS) — 3-year DFS

Trial sites (3)

Facility	City	Region
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology	Wuhan	Hubei
Qilu Hospital，Shandong University	Jinan	Shandong
Women's Hospital, School of Medicine, Zhejiang University	Hangzhou	Zhejiang

More Ding Ma trials in China

The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma Active, not recruiting

Evaluation of AK104 (Cadonilimab) Combined with Chemotherapy for Recurrent or Metastatic Small Cell Neuroendocrine Carcinoma of the Cervix Enrolling by invitation

Other trials for the same condition

Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma Recruiting

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer Active, not recruiting

A Study of LY4257496 in Participants With Cancer (OMNIRAY) Recruiting

Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer Active, not recruiting

Fertility-sparing Therapy for Patients With Stage IA Endometrial Cancer Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT01820884 on ClinicalTrials.gov ↗ ← All trials in China